Nektar Therapeutics’ (Nasdaq: NKTR) shares closed up a massive 82.6% at $0.98 yesterday, after it revealed announced that efficacy data previously generated by former partner Eli Lilly (NYSE: LLY) for Rezpeg (rezpegaldesleukin) that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly.
The erroneous data is from two Phase Ib studies for Rezpeg that were conducted by Lilly. The new and corrected data highlight the important potential of Rezpeg to help patients battling atopic dermatitis (AtD), a chronic skin condition that afflicts nearly 10% of Americans.
On the basis of a study of rezpegaldesleukin as a treatment for systemic lupus erythematosus (SLE) that did not achieve its goals, Lilly returned rights for the candidate to Nektar in April this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze